HTI 501Alternative Names: HTI-501; Recombinant human cathepsin L - Halozyme Therapeutics; rHuCAT-L
Latest Information Update: 29 Sep 2015
At a glance
- Originator Halozyme Therapeutics
- Mechanism of Action Cathepsin L modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cellulite